Argent BioPharma Limited

OTCPK:RGTL.F Stock Report

Market Cap: US$3.0m

Argent BioPharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Roby Zomer

Chief executive officer

AU$2.4m

Total compensation

CEO salary percentage12.96%
CEO tenure10.5yrs
CEO ownership5.4%
Management average tenureless than a year
Board average tenure5.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roby Zomer's remuneration changed compared to Argent BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-AU$9m

Sep 30 2025n/an/a

-AU$13m

Jun 30 2025AU$2mAU$316k

-AU$18m

Mar 31 2025n/an/a

-AU$20m

Dec 31 2024n/an/a

-AU$23m

Sep 30 2024n/an/a

-AU$20m

Jun 30 2024AU$417kAU$387k

-AU$18m

Mar 31 2024n/an/a

-AU$17m

Dec 31 2023n/an/a

-AU$17m

Sep 30 2023n/an/a

-AU$19m

Jun 30 2023AU$354kAU$354k

-AU$21m

Mar 31 2023n/an/a

-AU$22m

Dec 31 2022n/an/a

-AU$23m

Sep 30 2022n/an/a

-AU$22m

Jun 30 2022AU$629kAU$422k

-AU$20m

Mar 31 2022n/an/a

-AU$19m

Dec 31 2021n/an/a

-AU$18m

Sep 30 2021n/an/a

-AU$17m

Jun 30 2021AU$481kAU$281k

-AU$16m

Dec 31 2020n/an/a

-AU$13m

Sep 30 2020n/an/a

-AU$16m

Jun 30 2020AU$440kAU$290k

-AU$19m

Compensation vs Market: Roby's total compensation ($USD1.72M) is above average for companies of similar size in the US market ($USD655.10K).

Compensation vs Earnings: Roby's compensation has increased whilst the company is unprofitable.

CEO

Roby Zomer (46 yo)

10.5yrs
Tenure
AU$2,435,524
Compensation

Mr. Roby Reuven Zomer is C.O.O of Onassis Holdings Corp. Mr. Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and serves as its CEO and Managing Director an...

Leadership Team

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founderno dataAU$2.44m5.4%
$ 161.5k
Shachar Shimony
Group General Counselno datano data1.23%
$ 36.9k
Amir Polak
Chief Pharmaceutical Development Officerno datano datano data
Nadya Lisovoder
Chief Medical Officerno datano datano data
Sasha Friedman
Head of Information Systemsno datano datano data
Yair Tal
Chief Information Security Officerno datano datano data
Andrew Chapman
Executive Directorless than a yearno datano data
Sanja Cacovich
Head of Non-Pharmaceutical Operationsless than a yearno datano data
Rowan Harland
Company Secretary3.4yrsno datano data
0.6yrs
Average Tenure

Experienced Management: RGTL.F's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder10.5yrsAU$2.44m5.4%
$ 161.5k
Andrew Chapman
Executive Directorless than a yearno datano data
Ross Grant Walker
Chairman of Strategic Advisory Boardno dataAU$32.00kno data
Uri Kramer
Member of Strategic Advisory Board10.1yrsno datano data
Wendyl D'Souza
Member of Medical Advisory Board8.1yrsno datano data
Daniel Robinson
Non-Executive Independent Director2.7yrsAU$44.00k0.45%
$ 13.4k
Shlomo Sadoun
Member of Advisory Board2.3yrsno datano data
5.4yrs
Average Tenure

Experienced Board: RGTL.F's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/19 01:14
End of Day Share Price 2026/08/11 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Argent BioPharma Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Salvatore Gaetano VerdolivaCanaccord Genuity
Robin DavisonCapital Network by Proactive Investors
Maxim JacobsEdison Investment Research